Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control

Chest

Volumn 128, Issue 4, 2005, Pages 1910-1920

  Nathan, Robert A ^a   Yancey, Steven W ^b   Waitkus Edwards, Kelli ^b   Prillaman, Barbara A ^b   Stauffer, John L ^b   Philpot, Edward ^b   Dorinsky, Paul M ^b   Nelson, Harold S ^c  

^a Asthma & Allergy Associates PC and Research Center   (United States)

^b GLAXOSMITHKLINE   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Asthma; Fluticasone propionate; Montelukast; Rhinitis; Salmeterol

Indexed keywords

ADVAIR DISKUS 100/50; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CREATININE; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; HYDROCORTISONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MONTELUKAST; PLACEBO; SALBUTAMOL; SHORT ACTING DRUG; TRIAMCINOLONE ACETONIDE;

ADULT; AEROSOL; ASTHMA; BACKACHE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG UTILIZATION; DYSPEPSIA; EPISTAXIS; FEMALE; FORCED EXPIRATORY VOLUME; HAY FEVER; HEADACHE; HUMAN; HYDROCORTISONE URINE LEVEL; MAJOR CLINICAL STUDY; MALE; NASAL PRURITUS; NOSE CONGESTION; OPEN STUDY; OUTCOMES RESEARCH; PATIENT SATISFACTION; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCORING SYSTEM; SNEEZING; SORE THROAT; SYMPTOM;

EID: 27144502654     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.4.1910     Document Type: Conference Paper

References (29)

1. Skoner D. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001; 108:S2-S8
2. Mannino DM, Homa DM, Akinbami LJ, et al. Surveillance for asthma-United States, 1980-1999. In: CDC Surveillance Summaries, March 29, 2002. MMWR Morb Mortal Wkly Rep 2002; 51(SS-1):1-13
3. Greisner WA, Settipane RJ, Settipane GA. Co-existence of asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Asthma Proc 1998; 19:185-188
4. Guerra S, Sherrill DL, Martinez FD, et al. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol 2002; 109:419-425
5. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis: I. Assessing the economic impact. J Allergy Clin Immunol 2001; 107:3-8
6. Stempel DA, Woolf R. The cost of treating allergic rhinitis. Curr Allergy Asthma Rep 2002; 2:223-230
7. Bousquet J, Van Cauwenberge P, Khaltaev N. Aria Workshop Group. World Health Organization. Allergic rhinitis and its impact on asthma J Allergy Clin Immunol 2001; 108(suppl): S147-S334
8. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136:225-244
9. Crapo R, Morals A, Gardner R. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123:659-664
10. Polgar G, Promadhat V. Pulmonary function testing in children: techniques and standards. Philadelphia, PA: Saunders, 1971; 1-269
11. Ratner PH, Howland WC III, Arastu R, et al. Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Ann Allergy Asthma Immunol 2003; 90:536-542
12. Pullerits T, Praks L, Baker R, et al. Comparison of nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109:949-955
13. Ratner PH, Howland III WC, Jacobs RL, et al. Relief of sinus pain and pressure with fluticasone propionate aqueous nasal spray: a placebo-controlled trial in patients with allergic rhinitis. Allergy Asthma Proc 2002; 23:259-263
14. Nathan RA, Bronsky EA, Fireman P, et al. Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis. Ann Allergy 1991; 67:332-338
15. 1 receptor antagonist in allergic rhinitis: systematic review of randomized controlled trial. BMJ 1998; 317:219-224
16. Stempel DA, Thomas M. Treatment of allergic rhinitis: an evidenced-based evaluation of nasal corticosteroids versus non-sedating antihistamines. Am J Manag Care 1998; 4:89-96
17. Dykewicz MS, Fineman S, Skoner DP. Joint task force summary statement on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol 1998; 81:474-477
18. Nelson HS. Prospects for antihistamines in the treatment of asthma. J Allergy Clin Immunol 2003; 112:S96-S100
19. Phipatanakul W, Nowak-Wegrzyn A, Eggleston PA, et al. The efficacy of montelukast in the treatment of cat allergen-induced asthma in children. J Allergy Clin Immunol 2002; 109:794-799
20. Nathan RA. Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments. Ann Allergy Asthma Immunol 2003; 90: 182-190
21. Foresi A, Pelucchi A, Cherson G, et al. Once daily intranasal fluticasone propionate (200 μg) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 1996; 98:274-282
22. Watson WTA, Becker AB, Simons FER. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway responsiveness. J Allergy Clin Immunol 1993; 91:97-101
23. Crystal-Peters J, Neslusan C, Crown WH, et al. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002; 109:57-62
24. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001; 357:2007-2011
25. Fluticasone Propionate Collaborative Pediatric Working Group. Treatment of seasonal allergic rhinitis with once-daily intranasal fluticasone propionate therapy in children. J Pediatr 1994; 125:628-634
26. Vargas R, Dockhorn RJ, Findlay R, et al. Effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary axis. J Allergy Clin Immunol 1998; 102:191-197
27. Li JTC, Ford LB, Chervinsky P, et al. Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. J Allergy Clin Immunol 1999; 103:1062-1068
28. Turktas I, Ozkaya O, Bostanci I, et al. Safety of inhaled corticosteroid therapy in young children with asthma. Ann Allergy Asthma Immunol 2001; 86:649-654
29. Lipworth BJ, Wilson AM. 24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids. Thorax 1999; 54:20-26